Drug updated on 4/30/2024
| Dosage Form | Tablet (oral; 5 mg, 15 mg) |
| Drug Class | Sodium glucose co-transporter 2 (SGLT2) Inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Ertugliflozin (Steglatro) is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus.
- A total of 14 systematic reviews/meta-analyses were reviewed, providing insights into the safety and effectiveness of this drug compared to other treatments for type 2 diabetes.
- In terms of renal function and cardiovascular safety, Ertugliflozin (Steglatro) was found to reduce estimated glomerular filtration rate (eGFR), but did not significantly increase the risk of acute myocardial infarction or angina pectoris.
- The drug appears to mainly increase the risk of genital mycotic infections similar to other SGLT2 inhibitors; however, it showed a reduced risk for urinary tract infection at a dosage level of 5 mg.
- Effectiveness studies revealed that Ertugliflozin (Steglatro) significantly improved glycemic control by reducing HbA1c and fasting plasma glucose levels both as monotherapy and in combination strategies comparable with empagliflozin, canagliflozin, dapagliflozin etc., which are also SGLT2 inhibitors used for managing T2DM patients' blood sugar levels.
- Additional benefits include reductions in body weight along with improvements in systolic/diastolic blood pressure - common beneficial effects seen across drugs within its class like empagliflozin or canagflizoin etc.
- Among high-risk patients suffering from T2DM who are prone towards cardiovascular diseases, while effective overall it may offer slightly different degrees protection against cardiorenal events when compared against others within its class such as empagliofizin or canagliofizin etc.
- Special attention should be given during prescription among diverse populations including those belonging from various ethnicities, disease severities and those with concurrent conditions as the efficacy of Ertugliflozin (Steglatro) may vary among these subgroups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Steglatro (ertugliflozin) Prescribing Information. | 2023 | Merck Sharp & Dohme LLC., Rahway, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. | 2019 | National Institute for Health and Care Excellence |
| Australian public assessment report for ertugliflozin, ertugliflozin / sitagliptin, ertugliflozin / metformin. | 2019 | Therapeutic Goods Administration |